ISPOR SEVENTH ANNUAL INTERNATIONAL MEETING AWARDS RECIPIENTS

At the ISPOR Seventh Annual International Meeting, May 19-22, 2002,
Hyatt Regency Crystal City, Arlington, Virginia, the scientific merit exhibited in contributed poster and podium presentations was recognized with Contributed Paper Award in the following categories: Overall, students and new investigators. This year, the ISPOR Awards Committee evaluated approximately 48 podium presentations and 350 poster presentations.

A SPECIAL THANKS GOES TO Les Noe RPh, MPA, Co-Chair, ISPOR Contributed Research Paper Awards Task Force -- Poster Presentations AND HIS COMMITTEE, AS WELL AS TO Mark Nuijten MD, MBA, Co-Chair, ISPOR Contributed Research Paper Awards Task Force -- Podium Presentations AND HIS COMMITTEE, FOR ALL THEIR EFFORTS IN SELECTING THE WINNERS.

BEST CONTRIBUTED PAPER AWARDS PODIUM PRESENTATIONS

MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ą CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
Drummond M1, Becker D2, Hux M2, Chancellor J3, Duprat-Lomon I4, Sagnier PP5, 1Innovus Research (UK) Ltd. and University of York, Heslington, York, UK; 2Innovus Research Inc, Burlington, ON, Canada; 3Innovus Research (UK) Ltd, Amersham, Buckinghamshire, UK; 4Bayer Pharma, Puteaux, France; 5Bayer plc, Slough, UK

COMPARING RECENT CARDIOVASCULAR MEDICATIONS USING AN NNT MODEL
Caro J1, Ishak K2, Caro I2, Migliaccio-Walle K1, 1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval,
QC, Canada

COMPARISON OF TREATMENT COST FOR DEPRESSION BETWEEN FLUOXETINE, PAROXETINE, SERTRALINE AND VENLAFAXINE USING MANAGED CARE CLAIMS DATA
Curkendall SM1, Goehring EL1, She D1, Pezzullo JC2, Jones JK1, 1The Degge Group, Ltd, Arlington, VA, USA; 2Georgetown University, Washington, DC, USA

BEST NEW INVESTIGATOR PODIUM PRESENTATION

THE BURDEN OF DEPRESSION IN CANADA
Desjardins B1, Laurier C2, 1 University of Montreal, Faculty of Pharmacy, Merck Frosst Canada Ltd, Kirkland, QC; 2 University of Montreal, Montreal, QC, Canada

TOTAL HEALTHCARE EXPENDITURES FOR MIGRAINE PATIENTS ASSOCIATED WITH CHOICE OF DRUG THERAPY
Schabert VF1, Esposito D1, Bowers BW2, Rousey A1, Tillotson F1, 1The MEDSTAT Group, Santa Barbara, CA, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA

IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY?
Benner JS1, Ganz DA1, Weinstein MC2, Neumann PJ2, Glynn RJ1, Avorn J1, 1Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; 2Harvard School of Public Health, Boston, MA, USA

BEST STUDENT PODIUM PRESENTATION

AN ITEM ANALYSIS OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) USING CLASSICAL TEST THEORY AND ITEM RESPONSE THEORY METHODS
Ayyar Krishnan A1, Kwong WJ2, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA

FDA REGULATORY ACTIONS AGAINST MISLEADING OR UNSUBSTANTIATED ECONOMIC AND QUALITY-OF-LIFE CLAIMS: AN ANALYSIS OF WARNING LETTERS AND NOTICES OF VIOLATION
Stewart KA, Neumann PJ, Harvard School of Public Health, Boston, MA, USA

COST-EFFECTIVENESS OF NEW RAPID SCREENING TECHNOLOGIES FOR GONORRHEA IN URBAN EMERGENCY ROOM DEPARTMENTS
Aledort JE, Goldie SJ, Harvard University, Boston, MA, USA

ISPOR Best Contributed Poster Presentation Awards

BEST CONTRIBUTED PAPER AWARDS POSTER PRESENTATIONS

EXCESS MORTALITY AND COSTS ASSOCIATED WITH SERIOUS FUNGAL INFECTIONS AMONG ELDERLY CANCER PATIENTS: FINDINGS FROM LINKED SEER-MEDICARE DATA
Menzin J1, Lang K1, Friedman M1, Dixon D1, Marton J2, Wilson J2, 1Boston Health Economics, Waltham, MA, USA; 2Pfizer, Inc, New York, NY, USA

A BUDGET IMPACT ANALYSIS OF EARLY REFERRAL TO A NEPHROLOGIST FOR ELDERLY MEDICARE PATIENTS WITH END-STAGE RENAL DISEASE
Shih YCT1, Guo AM2, Prasad M1, Just PM2, 1MEDTAP International Inc, Bethesda, MD, USA; 2Baxter Healthcare Corporation, Deerfield, IL, USA

COST-EFFECTIVENESS OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Grima D1, Marshall D1, Weinstein M2, Wong J3, Kleinman S4, AuBuchon J5, 1Innovus Research Inc, Burlington, ON, Canada; 2Harvard School of Public Health, Boston, MA, USA; 3New England Medical Center, Boston, MA, USA; 4Kleinman Biomedical Research, Victoria, BC, Canada; 5Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA

BEST NEW INVESTIGATOR POSTER PRESENTATION

AN ECONOMIC MODEL FOR GASTROINTESTINAL RISK STRATIFICATION COMPARING COX-2 INHIBITORS TO TRADITIONAL NSAIDS FOR ARTHRITIS TREATMENT
DeLattre ML1, Schaefer MG2, Morreale AP2, Plowman BK2, 1VA San Diego Healthcare System/University of the Pacific, San Diego, CA, USA; 2VA San Diego Healthcare System, San Diego, CA, USA

HEALTH CARE RESOURCES UTILIZATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Lachaine J1, Bradley-Kennedy C2, 1University of Montreal, Montreal, QC, Canada; 2Boehringer Ingelheim Canada Ltd, Burlington, QC, Canada

PREVENTABLE DRUG-RELATED MORBIDITY AND MORTALITY IN OLDER ADULTS: A CANADIAN COST-OF-ILLNESS MODEL
Kidney T, MacKinnon NJ, Dalhousie University, Halifax, NS, Canada

BEST STUDENT POSTER PRESENTATION

THE IMPACT OF ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA
Ayyar Krishnan A, Christensen DB, University of North Carolina, Chapel Hill, NC, USA

ECONOMIC CONSEQUENCES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A NATIONAL SAMPLE OF US ADULTS
Sendersky V1, Law AW2, Gause D3, Sung J3, 1Duke University/Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Duke University, Durham, NC, USA; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

LONG-TERM BENEFITS OF CHEMOPREVENTIVE TAMOXIFEN AND ROUTINE MAMMOGRAPHY SCREENING IN WOMEN WHO ARE AT INCREASED RISK OF BREAST CANCER
Borker R, Madhavan S, Simon K, Higa G, Amonkar M, Scott V, West Virginia University, Morgantown, WV, USA